No profile data available.
Anebulo Pharmaceuticals, Inc. (ANEB) is a healthcare company in the poison treatment pharmaceuticals industry, based in Lakeway, United States, with about 2 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$8.48 million. In Q2 2026 (the quarter ended December 31, 2025) revenue was $0. Its market capitalization was $12.85 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended June 30, 2025; market data as of October 9, 2026.
, a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States.
Anebulo Pharmaceuticals reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$12.85 million as of October 9, 2026.
Listed companies of a similar size in the same industry (poison treatment pharmaceuticals) include Achieve Life Sciences, Inc. (ACHV), Aquestive Therapeutics, Inc. (AQST), Fennec Pharmaceuticals Inc. (FENC), Adial Pharmaceuticals, Inc. (ADIL).